+44-1518-081136Commentary - Journal of Systems Biology & Proteome Research (2023) Volume 4, Issue 2
Proteomic analysis of the human brain reveals novel insights into neurodegenerative diseases
Agus Sudiarawan*
Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, United States
- Corresponding Author:
- Agus Sudiarawan
Department of Obstetrics and Gynecology
University of Wisconsin-Madison
Madison, United States
Email: agus@sudiar.edu.us
Received: 24-Feb-2023, Manuscript No. AASBPR-23-91179; Editor assigned: 25-Feb-2023, PreQC No. AASBPR-23-91179(PQ); Reviewed: 09-Mar-2023, QC No. AASBPR-23-91179; Revised: 13-Mar-2023, Manuscript No. AASBPR-23-91179(R); Published: 20-Mar-2023, DOI: 10.35841/aasbpr-4.2.139
Citation: Sudiarawan A. Proteomic analysis of the human brain reveals novel insights into neurodegenerative diseases. J Syst Bio Proteome Res. 2023;4(2):139
Keywords
Proteomics, Human brain, Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS), Biomarkers.
Introduction
Proteomics is a powerful technology used to study the protein composition of cells, tissues, and organs. It allows the identification and quantification of proteins in a complex mixture and can provide insight into protein expression levels, post-translational modifications, and protein-protein interactions. Proteomic analysis of the human brain has revealed novel insights into neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease [1].
Alzheimer's disease is a progressive neurodegenerative disorder characterized by the accumulation of amyloid beta (Aβ) peptides and tau protein in the brain. Proteomic analysis of post-mortem brain tissue from Alzheimer's disease patients has identified changes in the expression of several proteins involved in Aβ metabolism, including the amyloid precursor protein (APP), which is processed to form Aβ peptides. Additionally, proteomic analysis has identified alterations in the expression of proteins involved in synaptic function and neurotransmitter signaling, which are disrupted in Alzheimer's disease. These changes provide insight into the molecular mechanisms underlying Alzheimer's disease and could lead to the development of novel therapeutics.
Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain. Proteomic analysis of post-mortem brain tissue from Parkinson's disease patients has identified alterations in the expression of several proteins involved in mitochondrial function, oxidative stress, and protein degradation. These changes suggest that defects in these pathways may contribute to the pathogenesis of Parkinson's disease. Furthermore, proteomic analysis has identified changes in the expression of proteins involved in neurotransmitter signaling, including dopamine transporters and receptors, which are disrupted in Parkinson's disease. These findings could lead to the development of new therapeutic approaches for Parkinson's disease [2].
Huntington's disease is a genetic neurodegenerative disorder characterized by the accumulation of mutant huntingtin protein in the brain. Proteomic analysis of brain tissue from Huntington's disease patients has identified alterations in the expression of several proteins involved in protein folding, degradation, and the stress response. These changes suggest that defects in protein quality control pathways may contribute to the pathogenesis of Huntington's disease. Additionally, proteomic analysis has identified changes in the expression of proteins involved in synaptic function and neurotransmitter signaling, which are disrupted in Huntington's disease. These findings provide insight into the molecular mechanisms underlying Huntington's disease and could lead to the development of novel therapeutics [3].
Proteomic analysis has also been used to identify potential biomarkers for neurodegenerative diseases. Biomarkers are measurable indicators of disease status that can be used to diagnose or monitor disease progression. Proteomic analysis of cerebrospinal fluid (CSF) and blood samples from patients with neurodegenerative diseases has identified several proteins that are differentially expressed compared to healthy controls. For example, CSF levels of tau protein are elevated in Alzheimer's disease patients, and alpha-synuclein levels are elevated in Parkinson's disease patients. These biomarkers could be used to diagnose neurodegenerative diseases at an early stage and monitor disease progression [4].
Proteomic analysis has also been used to identify potential therapeutic targets for neurodegenerative diseases. Therapeutic targets are molecules or pathways that can be targeted by drugs to treat or prevent disease. Proteomic analysis of brain tissue from animal models of neurodegenerative diseases has identified several proteins that are involved in disease pathogenesis and could be targeted by therapeutics. For example, in a mouse model of Alzheimer's disease, proteomic analysis identified a protein called SORL1, which regulates the processing of APP to form Aβ peptides. Treatment with a drug that enhances SORL1 expression reduced Aβ accumulation and improved cognitive function in the mice. This finding suggests that targeting SORL1 could be a viable therapeutic strategy for Alzheimer's disease [5].
Conclusion
Proteomic analysis of the human brain has provided novel insights into the pathophysiology of neurodegenerative diseases. The identification of disease-specific biomarkers and changes in protein expression levels have improved our understanding of disease mechanisms and can aid in early diagnosis and targeted therapies. The use of advanced technologies such as mass spectrometry and bioinformatics tools have facilitated the discovery of new drug targets and the development of personalized medicine. However, further research is needed to validate these findings and translate them into clinical applications. Ultimately, the application of proteomics to neurodegenerative diseases holds great promise for improving patient outcomes and enhancing our understanding of the brain.
References
- Jansson J, Willing B, Lucio M, et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PloS One. 2009;4(7):e6386.
- Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103.
- Xiong W, Giannone RJ, Morowitz MJ, et al. Development of an enhanced metaproteomic approach for deepening the microbiome characterization of the human infant gut. J Proteome Res. 2015;14(1):133-41.
- Heinken A, Thiele I. Anoxic conditions promote species-specific mutualism between gut microbes in silico. Appl Environ Microbiol. 2015;81(12):4049-61.
- Verberkmoes NC, Russell AL, Shah M, et al. Shotgun metaproteomics of the human distal gut microbiota. ISME J. 2009;3(2):179-89.
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref